What’s happening?
The Pharmacy Compounding Advisory Committee (PCAC) - the committee that advises FDA on matters related to drug compounding - met today to discuss whether to continue allowing four crucial ingredients to be compounded (choline chloride, melatonin, methylcobalamin, and oxitriptan).
PCAC listened to testimonies, reviewed patient stories, and took into consideration the FDA staff's recommendations before voting for each compounded ingredient. Their votes determined if each ingredient can or cannot continue to be compounded.
The AANP, along with many coalition partners, has spent several years submitting information and testifying to defend the use of compounded ingredients. Our grateful thanks to Dr. Paul Anderson, who spoke on behalf of the AANP this afternoon and in past PCAC sessions.
Important: Please note, PCAC reviewed the compounded form of these ingredients, not just the ingredient itself.
Ingredients & the status of their ability to compound are below.